earnings
confidence high
sentiment positive
materiality 0.75
Neurocrine reports 2021 INGREZZA sales of $1.1B, guides 2022 sales $1.25-1.35B
NEUROCRINE BIOSCIENCES INC
2021-FY EPS reported
$0.92
revenue$1,133,500,000
- Total revenue FY 2021 $1.13B (+8% YoY); INGREZZA net sales $1.09B (+10% YoY).
- GAAP net income $89.6M ($0.92 diluted EPS); non-GAAP net income $185.8M ($1.90 diluted EPS).
- Q4 2021 GAAP net loss $7.3M ($0.08 loss per share) due to $100M Sosei Heptares upfront fee.
- 2022 INGREZZA guidance $1.25-1.35B (+20% YoY midpoint); minimal federal cash taxes expected in 2022.
- Phase III KINECT-HD valbenazine met primary endpoint; sNDA for Huntington chorea planned H2 2022.